Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

Release time:

2025-03-01

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the sector index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance. Among sub-sectors, medical R&D outsourcing led gains with a 11.3% increase, while offline pharmacies posted the weakest performance, falling by 3.06%. In terms of valuation, the current price-to-earnings ratio (TTM) stands at 26 times, remaining near a decade-low. Market capital continues to flow into hard-tech areas such as innovative drugs and AI-driven healthcare, and positive policy signals have further strengthened expectations for a bottom reversal in the sector.

Despite the promising prospects of AI in healthcare, its development continues to face challenges such as data compliance and lengthy clinical validation cycles. Currently, the market is increasingly focused on midstream platform companies in the “AI + Healthcare” space, which can rapidly translate technological advances into practical applications by integrating algorithms, data, and clinical resources. At the same time, emerging technologies such as stem cell therapy and gene editing are increasingly demonstrating synergistic effects with AI, potentially becoming key competitive arenas in the next phase of industry development. Notably, striking a balance between the pace of technological iteration and regulatory adaptability will be a critical determinant of the industry’s growth trajectory.

Related News

Overview of Bioanalytical Methods for Cell Therapy Products

Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.

2026-04-03

Bioanalytical Strategies for CGT Products: Selected Developments and Validation of qPCR/ddPCR Methodologies

With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.

2026-04-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road

Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.

2025-03-01

Share